Exercise helps breast cancer patients with the physical and mental side effects of treatment, a new Loughborough University study has found, and ultimately it may improve disease prognosis.
Mar 25, 2022
0
149
Men with microscopic evidence of prostate cancer spreading to their pelvic lymph nodes (LNs) following the surgical resection of the prostate and pelvic lymph nodes (LN) are at a very high risk of dying from prostate cancer. ...
Mar 15, 2022
0
3
For patients with sentinel lymph node (SLN)-positive melanoma, fewer patients are undergoing completion lymph node dissection (CLND) and more are receiving adjuvant systemic therapy, according to study published online Jan. ...
Mar 9, 2022
0
2
New studies aim to clarify the relationship between obesity and breast cancer, and explore the potential role of bariatric surgery in reducing this risk, according to a review published online in Obesity journal.
Feb 23, 2022
0
8
An older woman's oestrogen levels may be linked to her chances of dying from COVID-19, with higher levels of the hormone seemingly protective against severe infection, suggests research published in the open access journal ...
Feb 14, 2022
0
28
Treating women diagnosed with one type of early-stage breast cancer with the monoclonal antibody trastuzumab after surgery reduces the risk of the cancer returning, reports a research team led by University of Saskatchewan ...
Jan 31, 2022
0
54
For patients with Parkinson disease on levodopa therapy, patient-rated quality of life is similar for those receiving adjuvant therapy with dopamine agonists compared with dopamine reuptake inhibitors (DRIs); and among DRIs, ...
Dec 29, 2021
0
18
A common strategy to make vaccines more powerful is to deliver them along with an adjuvant—a compound that stimulates the immune system to produce a stronger response.
Dec 3, 2021
1
137
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumor resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute ...
Oct 1, 2021
0
5
The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo. The late breaking results of the KEYNOTE-716 trial are presented ...
Sep 20, 2021
0
4
